BioMark says AI-driven blood test model hits 96.9% ROC-AUC in lung cancer study

PUBT · 2d ago
BioMark says AI-driven blood test model hits 96.9% ROC-AUC in lung cancer study
  • BioMark highlighted two peer-reviewed studies supporting its metabolomics liquid biopsy for early NSCLC screening, bringing total publications to five in nine months.
  • Biomedicines paper dated Aug. 18, 2026 reported a 24-feature SEFA model with 96.9% test ROC-AUC, 94.4% accuracy in 800 participants.
  • International Journal of Molecular Sciences paper dated Aug. 17, 2026 reported a 19-metabolite panel in 1,038 patients with AUC about 0.91.
  • Research emphasized AI-driven panel reduction to cut assay complexity, lower testing costs, improve interpretability, limit smoking-related confounding.
  • Company positioned results as de-risking commercialization, supporting external validation trials, advancing regulatory submissions in North America.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMark Diagnostics Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202608250830NEWSFILECNPR____20260825_311231_1) on August 25, 2026, and is solely responsible for the information contained therein.